Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 1996 Nov 9;313(7066):1169-74.
doi: 10.1136/bmj.313.7066.1169.

New antiepileptic drugs: a systematic review of their efficacy and tolerability

A G Marson  1 , Z A Kadir, D W Chadwick
Affiliations
Meta-Analysis

New antiepileptic drugs: a systematic review of their efficacy and tolerability

A G Marson et al. BMJ. .

Abstract

Objectives: To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy.

Design: Systematic review of published and unpublished randomised controlled trials of add-on treatment with new antiepileptic drugs.

Subjects: 20 published and eight unpublished trials representing 3883 patients with refractory partial epilepsy.

Main outcome measures: Proportion of patients who (a) showed 50% or greater reduction in frequency of seizures (50% responders) and (b) withdrew from each study for any reason.

Results: Odds ratios (95% confidence intervals) relative to placebo for 50% responders were 2.29 (1.53 to 3.43) for gabapentin, 2.32 (1.47 to 3.68) for lamotrigine, 3.03 (2.01 to 4.58) for tiagabine, 4.22 (2.80 to 6.35) for topiramate, 3.68 (2.45 to 5.51) for vigabatrin, and 2.47 (1.36 to 4.47) for zonisamide. Odds ratios for withdrawal were 1.36 (0.75 to 2.49) for gabapentin, 1.19 (0.79 to 1.79) for lamotrigine, 1.81 (1.21 to 2.70) for tiagabine, 2.42 (1.43 to 4.11) for topiramate, 2.58 (1.26 to 5.27) for vigabatrin, and 5.70 (1.76 to 18.49) for zonisamide. Comparing results for each drug showed that all of the 95% confidence intervals overlapped, indicating that they were not significantly different in terms of efficacy and tolerability.

Conclusions: All six drugs were significantly better than placebo at reducing frequency of seizures. These results do not allow an evidence based choice between these drugs as we have no conclusive indication of differences in efficacy or tolerability.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1051-5 - PubMed
    1. Epilepsy Res. 1990 Nov;7(2):136-45 - PubMed
    1. Epilepsia. 1993 Mar-Apr;34(2):312-22 - PubMed
    1. J Neurol Neurosurg Psychiatry. 1993 May;56(5):448-53 - PubMed
    1. Epilepsy Res. 1993 May;15(1):67-73 - PubMed

MeSH terms